SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ATLANTA, Feb. 14, 2018 -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2017, after the close of the financial markets on Wednesday, February 28, 2018.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, March 1, 2018. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, March 1, 2018 9:00AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' Fourth Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations."
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
[email protected]
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
i[email protected]
